News from ptc therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 28, 2016, 16:30 ET

PTC Therapeutics to Participate at Upcoming Investor Conferences

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: -...

Jan 11, 2016, 08:00 ET

PTC Therapeutics Outlines Business Priorities for the Development and Commercialization of Translarna™ and Progress of the Company Pipeline

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a corporate update, which will be detailed at the company's presentation at the 34th...

Jan 08, 2016, 08:00 ET

PTC Completes Rolling NDA Submission to FDA and Submits Phase 3 ACT DMD Clinical Trial Results to EMA for Translarna™ (ataluren) for Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the completion of its rolling submission of a New Drug Application (NDA) to the United States...

Jan 07, 2016, 08:00 ET

Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development

 PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that RG7916, an additional SMN2 splicing modifier from the company's joint development...

Jan 06, 2016, 16:30 ET

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 4, 2016 it approved non-statutory stock options to purchase an aggregate of...

Dec 23, 2015, 16:30 ET

PTC Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 34th Annual J.P. Morgan...

Dec 09, 2015, 08:00 ET

PTC Therapeutics and Massachusetts General Hospital Collaborate on Rare Disease Research

PTC Therapeutics, Inc. (Nasdaq: PTCT) has entered into a research collaboration with Massachusetts General Hospital (MGH, a Partners Healthcare...

Dec 04, 2015, 17:00 ET

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 3, 2015 it approved non-statutory stock options to purchase an aggregate of...

Nov 19, 2015, 08:00 ET

PTC Completes Enrollment of Phase 3 Clinical Trial of Translarna™ for Patients with Cystic Fibrosis

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT CF, the company's second Phase 3 clinical trial...

Nov 09, 2015, 16:05 ET

PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September...

Nov 03, 2015, 16:06 ET

PTC Therapeutics to Participate at Upcoming Investor Conferences

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced  that management will present a company update at the following conferences:...

Oct 29, 2015, 08:00 ET

PTC Therapeutics Announces Launch of STRIVE Grant Award Program for Cystic Fibrosis

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards...

Oct 27, 2015, 16:30 ET

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2015 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2015...

Oct 15, 2015, 16:05 ET

PTC Announces Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of...

Oct 04, 2015, 11:00 ET

Phase 2 Data from Spinal Muscular Atrophy Program to be Presented at the 20th International Annual Congress of the World Muscle Society

PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that clinical data from the company's joint development program with Roche and the SMA...

Oct 02, 2015, 19:10 ET

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 2, 2015 it approved non-statutory stock options to purchase an aggregate of...

Sep 30, 2015, 08:00 ET

PTC Therapeutics Submits European Application For Translarna™ for Cystic Fibrosis

 PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) has validated the submission of a variation...

Sep 04, 2015, 08:00 ET

PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award

 PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards...

Aug 21, 2015, 16:30 ET

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on August 20, 2015 it approved non-statutory stock options to purchase an aggregate...

Aug 14, 2015, 16:15 ET

PTC Therapeutics Announces Closing of $150 Million of Convertible Senior Notes

 PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced private offering of $150 million in aggregate...